165 related articles for article (PubMed ID: 23866897)
21. [Low-frequency, low-dose oral psoralen-UV-A therapy for mycosis fungoides].
Kluwig D; Yazdi AS
Hautarzt; 2020 Jan; 71(1):81-82. PubMed ID: 31768559
[No Abstract] [Full Text] [Related]
22. The influence of psoralen + ultraviolet A treatment on the duration of remission and prognosis in mycosis fungoides.
Oguz O; Engin B; Aydemir EH
J Eur Acad Dermatol Venereol; 2003 Jul; 17(4):483-5. PubMed ID: 12834475
[No Abstract] [Full Text] [Related]
23. A chart review of patients with early stage mycosis fungoides treated with psoralen plus UVA (PUVA).
Soung J; Muigai W; Amin N; Stern DK; Lebwohl MG
J Drugs Dermatol; 2005; 4(3):290-4. PubMed ID: 15898283
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of 8-methoxypsoralen vs. 5-methoxypsoralen plus ultraviolet A therapy in patients with mycosis fungoides.
Wackernagel A; Hofer A; Legat F; Kerl H; Wolf P
Br J Dermatol; 2006 Mar; 154(3):519-23. PubMed ID: 16445785
[TBL] [Abstract][Full Text] [Related]
25. Hyperpigmented mycosis fungoides: a case report.
Erbil H; Sezer E; Koseoglu D; Filiz N; Kurumlu Z; Bülent Taştan H; Demiriz M
J Eur Acad Dermatol Venereol; 2007 Aug; 21(7):982-3. PubMed ID: 17659014
[No Abstract] [Full Text] [Related]
26. Safety and efficacy of low-dose bexarotene and PUVA in the treatment of patients with mycosis fungoides.
Papadavid E; Antoniou C; Nikolaou V; Siakantaris M; Vassilakopoulos TP; Stratigos A; Stavrianeas N; Katsambas A
Am J Clin Dermatol; 2008; 9(3):169-73. PubMed ID: 18429646
[TBL] [Abstract][Full Text] [Related]
27. Bexarotene treatment of late-stage mycosis fungoides and Sézary syndrome: development of extracutaneous lymphoma in 6 patients.
Bouwhuis SA; Davis MD; el-Azhary RA; McEvoy MT; Gibson LE; Knudsen JM; Kist JM; Pittelkow MR
J Am Acad Dermatol; 2005 Jun; 52(6):991-6. PubMed ID: 15928617
[TBL] [Abstract][Full Text] [Related]
28. Bath-water PUVA therapy with 8-methoxypsoralen in mycosis fungoides.
Weber F; Schmuth M; Sepp N; Fritsch P
Acta Derm Venereol; 2005; 85(4):329-32. PubMed ID: 16191854
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of the efficacy of the combination of oral bexarotene and methotrexate for the treatment of early stage treatment-refractory cutaneous T-cell lymphoma.
Kannangara AP; Levitan D; Fleischer AB
J Dermatolog Treat; 2009; 20(3):169-76. PubMed ID: 19016373
[TBL] [Abstract][Full Text] [Related]
30. Combining rexinoids with psoralen-ultraviolet A sheds light on the management of mycosis fungoides.
Ahmed Z; Piguet V
Br J Dermatol; 2012 Sep; 167(3):467. PubMed ID: 22924948
[No Abstract] [Full Text] [Related]
31. Hyperpigmentation as a peculiar presentation of mycosis fungoides.
Lu YY; Wu CH; Lu CC; Hong CH
An Bras Dermatol; 2017; 92(5 Suppl 1):92-94. PubMed ID: 29267458
[TBL] [Abstract][Full Text] [Related]
32. Psoralen plus ultraviolet A +/- interferon-alpha treatment resistance in mycosis fungoides: the role of tumour microenvironment, nuclear transcription factor-kappaB and T-cell receptor pathways.
Wozniak MB; Tracey L; Ortiz-Romero PL; Montes S; Alvarez M; Fraga J; Fernández Herrera J; Vidal S; Rodriguez-Peralto JL; Piris MA; Villuendas Deceased R
Br J Dermatol; 2009 Jan; 160(1):92-102. PubMed ID: 18945306
[TBL] [Abstract][Full Text] [Related]
33. Narrowband UVB and PUVA in the treatment of mycosis fungoides: a retrospective study.
Ahmad K; Rogers S; McNicholas PD; Collins P
Acta Derm Venereol; 2007; 87(5):413-7. PubMed ID: 17721648
[TBL] [Abstract][Full Text] [Related]
34. Sustained remission of treatment-resistant cutaneous T-cell lymphoma with oral bexarotene.
Mehlmauer MA
Cutis; 2004 Jun; 73(6):417-20. PubMed ID: 15224787
[TBL] [Abstract][Full Text] [Related]
35. 308-nm excimer laser for the treatment of lymphomatoid papulosis and stage IA mycosis fungoides.
Kontos AP; Kerr HA; Malick F; Fivenson DP; Lim HW; Wong HK
Photodermatol Photoimmunol Photomed; 2006 Jun; 22(3):168-71. PubMed ID: 16719874
[No Abstract] [Full Text] [Related]
36. Bexarotene and narrowband ultraviolet B phototherapy combination treatment for mycosis fungoides.
Lokitz ML; Wong HK
Photodermatol Photoimmunol Photomed; 2007 Dec; 23(6):255-7. PubMed ID: 17986063
[TBL] [Abstract][Full Text] [Related]
37. Photo-sensitive mycosis fungoides: a new variant?
Haber R; Ram-Wolff C; Laly P; Bouaziz JD; Jachiet M; Rivet J; Bagot M
Eur J Dermatol; 2017 Apr; 27(2):181-182. PubMed ID: 27869099
[No Abstract] [Full Text] [Related]
38. Follicular mycosis fungoides: successful treatment with oral bexarotene.
Shistik G; Scalf LA; Fenske N; Glass LF
J Drugs Dermatol; 2004; 3(3):301-4. PubMed ID: 15176165
[TBL] [Abstract][Full Text] [Related]
39. Folliculotropic mycosis fungoides with CD30+ large-cell transformation in a young woman: beneficial effect of bexarotene.
Mitteldorf C; Stadler R; Bertsch HP; Neumann C
Br J Dermatol; 2007 Mar; 156(3):584-6. PubMed ID: 17300259
[No Abstract] [Full Text] [Related]
40. [Treatment of mycosis fungoides with PUVA and bexarotene].
Ortiz-Romero PL; Sánchez-Largo ME; Sanz H; García-Romero D; Rosales B; Valverde R; Arrue I; Polo I; Ruiz D; Fernández-Herrera J; Vanaclocha F
Actas Dermosifiliogr; 2006 Jun; 97(5):311-8. PubMed ID: 16956562
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
